Viridian Ebitda from 2010 to 2024
| 0K1R Stock | 21.75 0.38 1.72% |
EBITDA | First Reported 2013-03-31 | Previous Quarter -63.9 M | Current Value -75.6 M | Quarterly Volatility 23.5 M |
Check Viridian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 391.8 K, Interest Expense of 1.9 M or Selling General Administrative of 99.7 M, as well as many indicators such as . Viridian financial statements analysis is a perfect complement when working with Viridian Therapeutics Valuation or Volatility modules.
Viridian | Ebitda |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Viridian Stock Analysis
When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.